Genetics Institute Inc. (GENIZ)
Oppenheimer & Co. analyst Matthew Geller repeated a "market perform" rating on the Cambridge, Mass., company following the announcement of Phase II results showing that Neumega Interleukin-11 was effective in restoring platelets following chemotherapy (see Clinical Results, page B8).